Clinical trials

  • INSULIN HUMAN for Intestinal malabsorption
  • N/A for Cardiac arrest
  • TRIV-509 for Atopic dermatitis
  • INSULIN HUMAN for Intestinal malabsorption
  • PUMITAMIG for Advanced solid tumors
  • MK-1084 for KRAS G12C-mutant advanced solid tumors | Neoplasm malignant with KRAS G12C mutation
  • Clinical trial in Burn injury
  • ISATUXIMAB for Multiple myeloma|Newly diagnosed transplant ineligible multiple myeloma
  • PARP inhibitor for Fallopian tube cancer | Ovarian cancer | Extraovarian cancer
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Acute respiratory distress syndrome (non-resolving)
  • Fluciclovine (18F) for Multiple myeloma
  • Immunoglobulin A; Immunoglobulin G; Immunoglobulin M for Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Severe aplastic anemia | Recipients of allogeneic hematopoietic stem cell transplantation